Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other rare and metabolic indications. The company is headquartered in London, the United Kingdom.
| Revenue (TTM) | 839,000 |
| Gross Profit (TTM) | 667,000 |
| EBITDA | $-71.08M |
| Operating Margin | -3565.00% |
| Return on Equity | -92.60% |
| Return on Assets | -29.80% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $1.05 |
| Price-to-Book | 11.59 |
| Price-to-Sales (TTM) | 650.25 |
| EV/Revenue | 169.98 |
| EV/EBITDA | -5.78 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 197.20% |
| Shares Outstanding | $47.23M |
| Float | $27.46M |
| % Insiders | 21.77% |
| % Institutions | 44.55% |
Volatility is currently contracting
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.
Silence Therapeutics (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
I initiate Silence Therapeutics at a speculative Buy, driven by near-term divesiran/SLN124 catalysts in polycythemia vera (PV). SLN's mRNAi GOLD GalNAc-siRNA platform enables infrequent dosing and strong target knockdown, potentially differentiating divesiran from weekly competitors like Rusfertide. Phase 1 SANRECO data show promising phlebotomy reduction and symptom improvement, but safety and efficacy require confirmation in the pivotal Phase 2 readout (August 2026).
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Silence Therapeutics Plc (NASDAQ:SLN) shares are up during Friday's session. On Thursday, the company highlighted follow-up data from its Phase 1 SANRECO study of divesiran.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2026 Annual Congress. Divesiran data presented at EHA show improvem.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET. A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be avail.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archiv.
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SLN and any ticker you trade — then tracks every position and per-strategy win rate.
